RT Journal Article
SR Electronic
T1 Concordant Analysis of KRAS Status in Primary Colon Carcinoma and Matched Metastasis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4229
OP 4235
VO 30
IS 10
A1 PASCALE MARIANI
A1 MARICK LAE
A1 ARMELLE DEGEORGES
A1 WULFRAN CACHEUX
A1 EMMANUELLE LAPPARTIENT
A1 AUDREY MARGOGNE
A1 JEAN-YVES PIERGA
A1 VÉRONIQUE GIRRE
A1 LAURENT MIGNOT
A1 MARIE CHRISTINE FALCOU
A1 RÉMY-JACQUES SALMON
A1 OLIVIER DELATTRE
A1 PATRICIA DE CREMOUX
YR 2010
UL http://ar.iiarjournals.org/content/30/10/4229.abstract
AB KRAS somatic mutations are the main predictive factor for non response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (mCRC) patients. We compared KRAS mutational status in the primary tumour and the corresponding metastases (1 to 4 sites) in 38 mCRC patients. KRAS mutational status was analysed using direct sequencing, SNAPShot multiplex PCR and Scorpion Taqman PCR analysis. Results showed 54% of primary tumours had KRAS mutations. A concordance of 97% between primaries and metastatic sites was observed. A tumour heterogeneity was also demonstrated in 5% of mCRC. One case with three different primary tumours harboured three different KRAS mutations, and only one was represented in the unique metastasis of this patient. We concluded there was a high concordance in the KRAS status between the primary tumour and metastases. More than one informative block and more sensitive assay may increase the accuracy of KRAS status determination.